SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Businessman jump careful on cracked or broken graph. Job opportunity and career. concept of under pressure. risk, financial, and tax
Neurodegenerative disease
Inhibikase Scraps Parkinson’s Drug After Disappointing Mid-Stage Data
Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and abandoned assets in recent months.
January 30, 2025
 · 
2 min read
 · 
Tristan Manalac
San Francisco and Golden Gate Bridge Scene
Business
Deep Dive: JPM M&A Rush Just the Start, as Biopharma Insider Predicts Mega-Deals to Come
The J.P. Morgan Healthcare Conference started off with a flurry of deals that reinvigorated excitement across the biopharma industry. Johnson & Johnson moved to acquire Intra-Cellular Therapies for $14.6 billion, breaking a dealmaking barrier that kept Big Pharma’s 2024 biotech buyouts to under $5 billion.
January 29, 2025
 · 
1 min read
 · 
Annalee Armstrong
Group Of Employees Being Fired By Their Company.
Layoffs
I-Mab Cuts 27% of Workforce After Pipeline Re-Prioritization
The layoffs follow an announcement in early January that I-Mab will re-prioritize resources to focus on advancing a CLDN18.2 and 4-1BB bispecific antibody for gastric cancers.
January 29, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Illustration of employer’s hand holding employee who was laid off to drop him out of office
Layoffs
Zentalis Cuts 40% of Staff as it Eyes Phase II Readout For Lead Asset
The move is part of a strategic restructuring aimed at getting azenosertib to the market for patients with gynecological malignancies.
January 29, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Novo Nordisk's logo on the facade of its building in Germany
Approvals
Novo Expands GLP-1 Dominance With Ozempic Nod for Kidney Disease
The approval continues the trend of GLP-1s expanding into indications outside of diabetes and weight loss.
January 29, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Eli Lilly's biotechnology center in California
Pipeline
Lilly Cuts Mid-stage Relaxin Study in Chronic Kidney Disease for ‘Lack of Foreseeable Clinical Benefit’
The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an overlapping patient population.
January 29, 2025
 · 
2 min read
 · 
Tristan Manalac
Corporate headquarters of Novo Nordisk in Denmark
IRA
With Wegovy, Ozempic on the Line, Novo Asks Court to Speed Up IRA Complaint
The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the second round of the IRA drug price negotiation program, even as the pharma challenges the program.
January 29, 2025
 · 
1 min read
 · 
Tristan Manalac
Podcast
RFK Jr. Faces the Senate, Sage Rebuffs Biogen, Obesity Space Expands, More
Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees more action with new company launches, IPOs and fresh data; and experts get ready for an important era in the Duchenne muscular dystrophy space.
January 29, 2025
 · 
1 min read
 · 
Heather McKenzie
Robert F. Kennedy Jr.
FDA
How Might the FDA Evolve Under RFK Jr. and Makary?
Ahead of Robert F. Kennedy Jr.’s confirmation hearings, experts—and RFK’s own family—expressed concerns about his vaccine-related views, though the same experts are largely unfazed by the level of power he and Marty Makary could ultimately wield over the FDA.
January 29, 2025
 · 
7 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS